Can a more intense chemo regimen beat aggressive lymphoma?

NCT ID NCT07663175

Ongoing Knowledge-focused Sponsor: IRCCS San Raffaele Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks back at medical records of 500 adults with aggressive B-cell lymphoma that has a MYC gene change. Researchers want to see if a stronger chemotherapy plan called CARMEN leads to better survival and remission rates compared to other treatments. Since it's a review of past data, no new drugs or tests are being given.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CARMEN regimen (intensified chemotherapy)
What this could lead to: If successful, this study could help identify whether intensified chemotherapy improves survival and remission rates for patients with aggressive B-cell lymphomas with MYC rearrangement.
What could go wrong: This is a retrospective observational study, not a controlled trial, so results may be influenced by selection bias. The findings will need confirmation in prospective studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMAS WITH MYC REARRANGEMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Burkitt lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL LYMPHOMAS WITH MYC REARRANGEMENT

Contacts and locations

Locations

IRCCS Ospedale San Raffaele

Milan, Italy, 20132, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.